Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-89402638 in Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies
NCT06663319Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of JNJ-89402638 in colorectal cancer (CRC) and gastric cancer (GC) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events by Severity at 24 months and Number of Participants with Dose-Limiting Toxicity at 28 days. Started Oct 2024; status: recruiting.
02
Drugs
JNJ-89402638
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06663319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663319.